Fabry disease in patients under dialysis: A screening study and identification of a novel mutation

Detalhes bibliográficos
Autor(a) principal: Silva, Francisca Gomes
Data de Publicação: 2021
Outros Autores: Pestana, Nicole, Durães, José, Silva, Gil
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.26/38780
Resumo: Fabry disease (FD) is a rare systemic disease, with a large spectrum of disease severity. A GLA gene mutation in X‑chromosome leads to progressive accumulation of globotriaosylceramide (Gb3) in various organs. We screened all patients under dialysis from a single center for GLA gene changes. Enzymatic activity of alpha galactosidase A (α‑Gal A) and concentration of lyso‑Gb3 were determined in dried blood spots. Genetic study was performed in male patients with low α‑Gal A activity and in all female subjects. For all positive patients, a complete family study was performed. A total of 72 dialysis patients were screened. Sequence analysis was carried out in 53 patients (25 males). Heterozygous variants of the GLA gene were found in 4 patients (7.5%): c.937G>T (D313Y) in exon 6; c.352C>T (R118C) in exon 2; c.870G>C (M290I) in exon 6 and c.580A>G (T194A) in exon 4. Family screening was performed in a total of 17 subjects, with a GLA genetic variant prevalence of 58.8%. Unlike p.D313Y and p.R118C, well‑known non‑pathogenic polymorphisms, p.M290I is a controversial poorly described mutation. Reports about its phenotypic expression are crucial for a better understanding of its behavior. The recognition of the novel mutation p.T194A is importante for better knowledge of FD and its spectrum of clinical manifestations. These affected patients are expected to develop a classic and life‑threatening FD phenotype and an early diagnosis is essential for their treatment success.
id RCAP_b7d2b77a6a3b59279c32582f3f4abc0b
oai_identifier_str oai:comum.rcaap.pt:10400.26/38780
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Fabry disease in patients under dialysis: A screening study and identification of a novel mutationGenetic ScreeningX‑Linked genetic screeningChronic Renal FailureEnd‑Stage renal Kidney DiseaseHereditary Ventricular HypertrophyMadeira IslandRegião Autonoma da MadeiraPortugalFabry disease (FD) is a rare systemic disease, with a large spectrum of disease severity. A GLA gene mutation in X‑chromosome leads to progressive accumulation of globotriaosylceramide (Gb3) in various organs. We screened all patients under dialysis from a single center for GLA gene changes. Enzymatic activity of alpha galactosidase A (α‑Gal A) and concentration of lyso‑Gb3 were determined in dried blood spots. Genetic study was performed in male patients with low α‑Gal A activity and in all female subjects. For all positive patients, a complete family study was performed. A total of 72 dialysis patients were screened. Sequence analysis was carried out in 53 patients (25 males). Heterozygous variants of the GLA gene were found in 4 patients (7.5%): c.937G>T (D313Y) in exon 6; c.352C>T (R118C) in exon 2; c.870G>C (M290I) in exon 6 and c.580A>G (T194A) in exon 4. Family screening was performed in a total of 17 subjects, with a GLA genetic variant prevalence of 58.8%. Unlike p.D313Y and p.R118C, well‑known non‑pathogenic polymorphisms, p.M290I is a controversial poorly described mutation. Reports about its phenotypic expression are crucial for a better understanding of its behavior. The recognition of the novel mutation p.T194A is importante for better knowledge of FD and its spectrum of clinical manifestations. These affected patients are expected to develop a classic and life‑threatening FD phenotype and an early diagnosis is essential for their treatment success.Repositório ComumSilva, Francisca GomesPestana, NicoleDurães, JoséSilva, Gil2022-01-11T14:42:25Z2021-012021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.26/38780engPort J Nephrol Hypert 2021; 35(1): 29-3410.32932/pjnh.2021.xx.xxxinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-10T02:18:58Zoai:comum.rcaap.pt:10400.26/38780Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:34:37.489787Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Fabry disease in patients under dialysis: A screening study and identification of a novel mutation
title Fabry disease in patients under dialysis: A screening study and identification of a novel mutation
spellingShingle Fabry disease in patients under dialysis: A screening study and identification of a novel mutation
Silva, Francisca Gomes
Genetic Screening
X‑Linked genetic screening
Chronic Renal Failure
End‑Stage renal Kidney Disease
Hereditary Ventricular Hypertrophy
Madeira Island
Região Autonoma da Madeira
Portugal
title_short Fabry disease in patients under dialysis: A screening study and identification of a novel mutation
title_full Fabry disease in patients under dialysis: A screening study and identification of a novel mutation
title_fullStr Fabry disease in patients under dialysis: A screening study and identification of a novel mutation
title_full_unstemmed Fabry disease in patients under dialysis: A screening study and identification of a novel mutation
title_sort Fabry disease in patients under dialysis: A screening study and identification of a novel mutation
author Silva, Francisca Gomes
author_facet Silva, Francisca Gomes
Pestana, Nicole
Durães, José
Silva, Gil
author_role author
author2 Pestana, Nicole
Durães, José
Silva, Gil
author2_role author
author
author
dc.contributor.none.fl_str_mv Repositório Comum
dc.contributor.author.fl_str_mv Silva, Francisca Gomes
Pestana, Nicole
Durães, José
Silva, Gil
dc.subject.por.fl_str_mv Genetic Screening
X‑Linked genetic screening
Chronic Renal Failure
End‑Stage renal Kidney Disease
Hereditary Ventricular Hypertrophy
Madeira Island
Região Autonoma da Madeira
Portugal
topic Genetic Screening
X‑Linked genetic screening
Chronic Renal Failure
End‑Stage renal Kidney Disease
Hereditary Ventricular Hypertrophy
Madeira Island
Região Autonoma da Madeira
Portugal
description Fabry disease (FD) is a rare systemic disease, with a large spectrum of disease severity. A GLA gene mutation in X‑chromosome leads to progressive accumulation of globotriaosylceramide (Gb3) in various organs. We screened all patients under dialysis from a single center for GLA gene changes. Enzymatic activity of alpha galactosidase A (α‑Gal A) and concentration of lyso‑Gb3 were determined in dried blood spots. Genetic study was performed in male patients with low α‑Gal A activity and in all female subjects. For all positive patients, a complete family study was performed. A total of 72 dialysis patients were screened. Sequence analysis was carried out in 53 patients (25 males). Heterozygous variants of the GLA gene were found in 4 patients (7.5%): c.937G>T (D313Y) in exon 6; c.352C>T (R118C) in exon 2; c.870G>C (M290I) in exon 6 and c.580A>G (T194A) in exon 4. Family screening was performed in a total of 17 subjects, with a GLA genetic variant prevalence of 58.8%. Unlike p.D313Y and p.R118C, well‑known non‑pathogenic polymorphisms, p.M290I is a controversial poorly described mutation. Reports about its phenotypic expression are crucial for a better understanding of its behavior. The recognition of the novel mutation p.T194A is importante for better knowledge of FD and its spectrum of clinical manifestations. These affected patients are expected to develop a classic and life‑threatening FD phenotype and an early diagnosis is essential for their treatment success.
publishDate 2021
dc.date.none.fl_str_mv 2021-01
2021-01-01T00:00:00Z
2022-01-11T14:42:25Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.26/38780
url http://hdl.handle.net/10400.26/38780
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Port J Nephrol Hypert 2021; 35(1): 29-34
10.32932/pjnh.2021.xx.xxx
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134908013084672